Undisclosed iPSC-derived γδ-CAR T / Century Therap - LARVOL DELTA

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress (GlobeNewswire) - "Century Therapeutics...announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in Barcelona, Spain. The presentations will highlight data supporting the company’s emerging preclinical cell therapy pipeline and investigational programs for autoimmune diseases and cancer."

Preclinical • Immunology • Oncology

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) - "Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID)... Century Therapeutics...today announced that preclinical data from the Company’s iPSC-derived cell therapy platform will be presented in five posters at the 2024 ASH Annual Meeting to be held in San Diego, CA from December 7-10, 2024...This includes data relating to our enhanced Allo-Evasion via a novel CD300a TASR that demonstrated universal protection from NK cells, advanced CAR endo-domains that improve cytotoxicity and persistence, and differentiation-stage-specific promoters that allow for selective control of gene expression. Furthermore, we are encouraged by data demonstrating our CAR iNK and γδ iT cells’ potent preclinical ability to treat B-cell-mediated autoimmune diseases."

Preclinical • Immunology • Oncology